The effects of pulmonary vasodilating agents on right ventricular parameters in severe group 3 pulmonary hypertension: a pilot study
The effects of pulmonary vasodilating agents on right ventricular parameters in severe group 3 pulmonary hypertension: a pilot study
复制标题
DOI：
10.1086/688712
复制
发表时间：
2016-12-01
影响因子：
2.6
通讯作者：
Nishimura, Masaharu
中科院分区：
文献类型：
--
作者：
Sato, Takahiro;Tsujino, Ichizo;Nishimura, Masaharu
肺动脉高压（PAH）批准的血管扩张剂改善PAH患者的右心室（RV）功能。然而，pah批准的药物是否能改善肺部疾病相关肺动脉高压（lung- ph）的右心室形态和功能仍不清楚。我们的目的是前瞻性评估14例连续接受pah批准的血管扩张剂治疗的严重肺ph患者右心室体积和射血分数（RVEF）的变化。重度肺ph定义为平均肺动脉压(MPAP) >= 35 mmHg或MPAP >= 25 mmHg，心脏指数（L/min/m(2)）为
Pulmonary arterial hypertension (PAH)-approved vasodilators improve right ventricular (RV) function in patients with PAH. However, whether PAH-approved drugs ameliorate RV morphology and function in lung disease-associated pulmonary hypertension (lung-PH) remains unclear. We aimed to prospectively evaluate the changes in RV volume and ejection fraction (RVEF) in 14 consecutive severe lung-PH patients treated with PAH-approved vasodilators. Severe lung-PH was defined as a mean pulmonary arterial pressure (MPAP) of >= 35 mmHg or an MPAP of >= 25 mmHg with a cardiac index (L/min/m(2)) of